New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 7, 2014
09:04 EDTBAXBaxter names Hombach CFO
Baxter International announced that upon completion of the tax-free distribution of the company’s biopharmaceuticals business, Robert Hombach, currently CFO for Baxter International Inc., will be appointed CFO and will assume additional operational responsibilities for the independent biopharmaceuticals company. Hombach will report to Ludwig Hantson, who will serve as the new company’s CEO. James Saccaro will rejoin Baxter August 4, and will assume the role of CFO of Baxter International Inc. following completion of the transaction in 2015.
News For BAX From The Last 14 Days
Check below for free stories on BAX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
08:44 EDTBAXJPMorgan biotech analysts hold an analyst/industry conference call
Subscribe for More Information
September 15, 2014
09:16 EDTBAXOn The Fly: Pre-market Movers
Subscribe for More Information
09:01 EDTBAXBaxter announces FDA approval for RIXUBIS
(BAX) announced that the U.S. Food and Drug Administration has approved RIXUBIS for routine prophylactic treatment, control and prevention of bleeding episodes, and perioperative management in children with hemophilia B. RIXUBIS was the first recombinant factor IX approved for routine prophylaxis and control of bleeding episodes in the U.S. for adults living with this chronic condition. The approval is based on the results of a clinical trial investigating the efficacy and safety of RIXUBIS among 23 previously-treated male patients less than 12 years of age with severe or moderately severe hemophilia B. There were no reports of inhibitor development, no severe allergic reactions, and no thrombotic or treatment-related adverse events among the study participants. Baxter’s application for marketing approval for RIXUBIS for adults and pediatric patients is currently under review in the EU, with a regulatory decision expected later this year. The treatment also recently gained regulatory approval in Australia.
September 12, 2014
20:32 EDTBAXFDA approves Baxter's HYQVIA for treatment of primary immunodeficiency
Subscribe for More Information
September 11, 2014
08:15 EDTBAXBaxter says separation on track for mid-2015, new company to be called 'Baxalta'
Subscribe for More Information
September 8, 2014
05:47 EDTBAXBaxter price target raised to $96 from $85 at Piper Jaffray
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use